Detalhe da pesquisa
1.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Lancet HIV
; 11(5): e285-e299, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38692824
2.
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
J Clin Invest
; 133(4)2023 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36787249
3.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29898870
4.
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.
Sci Transl Med
; 9(419)2017 Dec 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29212716
5.
Evaluation of methods for oligonucleotide array data via quantitative real-time PCR.
BMC Bioinformatics
; 7: 23, 2006 Jan 17.
Artigo
Inglês
| MEDLINE | ID: mdl-16417622
6.
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
PLoS One
; 9(2): e87572, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24504509
7.
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.
PLoS One
; 8(1): e53629, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23349725
8.
Contrasting two frameworks for ROC analysis of ordinal ratings.
Med Decis Making
; 30(4): 484-98, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20147599
9.
The potential of genes and other markers to inform about risk.
Cancer Epidemiol Biomarkers Prev
; 19(3): 655-65, 2010 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-20160267